T1	Participants 37 71	prime alveolar macrophages in vivo
T2	Participants 579 628	healthy subjects who received D53 immunostimulant
T3	Participants 630 664	Twelve nonsmoking healthy subjects
T4	Participants 2026 2060	D53 immunostimulant in vivo primes
T5	Participants 2167 2232	effect of D53 immunostimulant against respiratory tract infection
